<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04129099</url>
  </required_header>
  <id_info>
    <org_study_id>PGC0006</org_study_id>
    <nct_id>NCT04129099</nct_id>
  </id_info>
  <brief_title>A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL</brief_title>
  <official_title>A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Yanda Ludaopei Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gracell Biotechnology Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Ludaopei Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hebei Yanda Ludaopei Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is an early, open, single-centered trial. The aim of this study is to evaluate the
      safety and tolerance of GC022F CAR-T cell immunotherapy in relapsed or refractory B-ALL. The
      study will include 18 subjects to receive GC022F therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of treatment related Adverse Events, CRS and Neurotoxicity (Safety and tolerability)</measure>
    <time_frame>2 years</time_frame>
    <description>Adverse events(AEs) will be collected and graded according to ASTCT consensus(for Cytokine Release Syndrome, CRS and Immune Effector Cell-Associated Neurotoxicity Syndrome, ICANS) and CTCAE v5.0(for AE except CRS/ICANS )</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CAR copies and concentration of GC022F in peripheral blood, bone marrow and CSF (amplification and persistence)</measure>
    <time_frame>2 years</time_frame>
    <description>GC022F CAR copies and cells in peripheral blood, bone marrow and CSF will be measured by qPCR and FCM in 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate of patients who received GC022F infusion (efficacy)</measure>
    <time_frame>2 years</time_frame>
    <description>Overall response rate will be estimated as the percents of patients who achieved CR or CRi.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentraiton of anti-GC022F antibody after infusion (humoral immune response)</measure>
    <time_frame>2 years</time_frame>
    <description>After GC022F infusion, GC022F antibody in peripheral blood will be measured in 2 years</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>B-cell Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>CAR-T treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will receive one dose of GC022F. GC022F dosage ranges from 6×10^4 to 1.5×10^5 CAR+T/Kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GC022F</intervention_name>
    <description>GC022F is the CAR-T cell immunotherapy targeted CD19 and CD22. The subjects will receive GC022F as one dose. The dosage ranges from 6×10^4 to 1.5×10^5 CAR+T/Kg.</description>
    <arm_group_label>CAR-T treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 2-70 years;

          2. Eastern cooperative oncology group (ECOG) performance status of 0 to 2;

          3. Life expectancy≥12 weeks;

          4. CD19 and/or CD22 tumor expression demonstrated in bone marrow or peripheral blood by
             flow cytometry;

          5. Relapsed or refractory B- ALL: a) Refractory B- ALL: MRD≥0.1% or fail to achieve a CR
             after 2 cycles of a standard induction chemotherapy regimen or one-line/multi-line
             salvage chemotherapy; b) Relapsed B- ALL: Relapse after remission for the first time
             in 12 months or relapse after one-line/multi-line salvage chemotherapy; Relapse is
             defined as MRD≥0.1% or recurrence of primitive cell in peripheral blood or bone
             marrow(&gt;5%) after remission; c)Relapse after autologous stem cell transplantation or
             allogeneic hematopoietic stem cell transplantation; Relapse is defined as above;
             d)Patients with Philadelphia chromosome positive(Ph+) ALL were eligible if they were
             intolerant to or had failed two lines of tyrosine kinase inhibitor (TKI) therapy, or
             had t315i mutation.

          6. Did not receive hematopoietic stem cell transplantation≤6 months prior to enrollment;

          7. Adequate organ function defined as: a) Creatinine clearance (as estimated by Cockcroft
             Gault) &gt;60 mL/min; b) Serum ALT/AST &lt;2.5 ULN; c) Total bilirubin &lt;1.5 ULN (subjects
             with Gilbert's syndrome≤3 ULN); d) Cardiac ejection fraction≥50%, no evidence of
             clinically significant pericardial effusion as determined by an ECHO; e) No clinically
             significant pleural effusion; f) Baseline oxygen saturation &gt;92% on room air;

          8. Females of reproductive age must be in non-lactation period. Females of childbearing
             potential must have a negative serum or urine pregnancy test. All subjects must use
             medical-approved-contraception (such as intrauterine device and contraceptive drugs)
             during the period of trial and in 2 years after cell transfusion therapy; Males should
             avoid sperm donation;

          9. Venous access can be established, peripheral blood mononuclear cells (PBMC) can be
             collected in researcher's judgement;

         10. The subject agrees to and sign informed consent form, willing and able to comply with
             the planned visit, research, treatment planning, laboratory and other test procedures.

        Exclusion Criteria:

          1. Isolated extra-medullary disease relapse;

          2. Central nervous system leukemia involved CNS-3;

          3. Concomitant malignancy other than cured non-melanoma skin cancer or cervical carcinoma
             in situ or localized prostate cancer or superficial bladder cancer or ductal carcinoma
             in situ or diagnosis of other malignancy exceeds 5 years without relapse or treatment
             during the 5 years;

          4. Any result of the following virology tests is positive: HIV; HCV; HBsAg; or HBCAb
             positive with HBV DNA copies positive; TPPA;

          5. Live vaccine ≤4 weeks prior to enrollment;

          6. For Ph+ ALL, TKI therapy ≤1 weeks prior to enrollment;

          7. Presence of ≥ grade 2 acute graft-versus-host disease (GVHD, Glucksberg criteria) or
             extensive chronic GVHD (Seattle criteria) that require treatment ≤4 weeks prior to
             enrollment, or during the study period the subject is required to receive anti- GCHD
             therapy in researcher's judgement;

          8. Presence of concomitant disease that require systemic steroids or other immune
             suppressive therapy during the study period in researcher's judgement;

          9. Allogeneic cell therapy (such as donor lymphocyte infusion, DLI) ≤4 weeks prior to
             enrollment;

         10. CNS stereotactic radiotherapy ≤4 weeks prior to enrollment;

         11. Toxicities related to previous therapy did not relieved to ≤1 grade, except
             hematological toxicity and alopecia;

         12. Known life-threatening hypersensitivity to cyclophosphamide or fludarabine, or
             presence of other intolerant conditions, or severe allergic constitution;

         13. Patients with active autoimmune disease (e.g., systemic lupus erythematosus, sjogren
             syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel
             disease, Hashimoto's thyroiditis, hypothyroidism which can be controlled by thyroid
             hormone replacement therapy is an exception);

         14. For patients that underwent or plan to undergo major surgical operation before CAR-T
             treatment, surgical operation happened ≤4 weeks prior to enrollment, or did not be
             fully recovered and clinically stable prior to enrollment, or be anticipated to
             undergo major surgical operation during the study;

         15. Any unstable cardiovascular diseases happened ≤6 months prior to enrollment, including
             but not limited to, unstable angina, myocardial infarction, heart failure (NYHA grade≥
             III grade), severe arrhythmia that require drug interference, cardiac
             angioplasty/coronary stent implantation/ cardiac bypass surgery ≤6 months prior to
             enrollment;

         16. Presence of central nervous system(CNS) disease or disease history, including
             epilepsy, cerebral Ischemia/bleeding, dementia, cerebellar disease, any autoimmune
             diseases that involve CNS;

         17. Presence of active infection that require therapy ≤2 weeks prior to apheresis;

         18. Any other conditions that researcher think it is inappropriate for the subject to
             anticipate the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junfang Yang, Bachelor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebei Yanda Ludaopei Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Junfang Yang, Bachelor</last_name>
    <phone>13522084342</phone>
    <email>Yangjunfang77@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hebei Yanda Ludaopei Hospital</name>
      <address>
        <city>Sanhe</city>
        <state>Hebei</state>
        <zip>065200</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peihua Lu, PhD&amp;MD</last_name>
      <phone>+86-0316-3306393</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 15, 2019</study_first_submitted>
  <study_first_submitted_qc>October 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

